Norge - norsk - Statens legemiddelverk

orion corporation - espoo - budesonid / formoterolfumaratdihydrat - inhalasjonspulver - 320 mikrog / 9 mikrog

Norge - norsk - Statens legemiddelverk

merck sharp & dohme b.v. - mycobacterium bovis bcg (bacillus calmette-guérin), stamme tice, levende, svekkede - pulver til intravesikalsuspensjon

Norge - norsk - Statens legemiddelverk

bluefish pharmaceuticals ab - ondansetronhydrokloriddihydrat - tablett, filmdrasjert - 8 mg

Norge - norsk - Statens legemiddelverk

bluefish pharmaceuticals ab - ondansetronhydrokloriddihydrat - tablett, filmdrasjert - 4 mg

Norge - norsk - Statens legemiddelverk

fresenius kabi norge as - halden - ondansetronhydrokloriddihydrat - injeksjonsvæske, oppløsning - 2 mg/ ml

Den europeiske union - norsk - EMA (European Medicines Agency)

endoceutics s.a. - prasterone - postmenopause menopause~~pos=headcomp - andre kjønnshormoner og modulatorer av genital systemet - intrarosa er indisert for behandling av vulvar og vaginal atrofi hos postmenopausale kvinner som har moderate til alvorlige symptomer.

Norge - norsk - Statens legemiddelverk

astrazeneca - budesonid / formoterolfumaratdihydrat - inhalasjonspulver - 320 mikrog/ dose / 9 mikrog/ dose

Den europeiske union - norsk - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuri, paroksysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Norge - norsk - Statens legemiddelverk

2care4 aps - prasteron - vagitorie - 6.5 mg